APREA THERAPEUTICS, INC.

(APRE)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
0.6466(c) 0.659(c) 0.745(c) 0.6684(c) 0.66(c) Last
762 621 1 043 551 1 062 704 340 483 240 035 Volume
+3.44% +1.92% +13.05% -10.28% -1.26% Change
More quotes
Estimated financial data (e) (USD)
More Financials
Company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or... 
More about the company
All news about APREA THERAPEUTICS, INC.
07:28aBerenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold R..
MT
05/17APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/17APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
CI
05/16APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/16TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
CI
05/16APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
05/16Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
GL
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Composite Index
CI
05/16ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
CI
03/16HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral..
MT
03/16RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Ra..
MT
03/15APREA THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Provi..
PU
03/15APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
03/15Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, ..
CI
More news
News in other languages on APREA THERAPEUTICS, INC.
05/16Aprea Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
05/16ATRIN PHARMACEUTICALS LLC A ACQUIS A : APRE) dans le cadre d'une opération de fusion inver..
03/15Aprea Therapeutics, Inc. annonce ses résultats pour l'année complète se terminant le 31..
03/15Aprea Therapeutics, Inc. fait le point sur ses activités commerciales
03/15Aprea Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 d..
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-76.71%15
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581